@misc{agent2026analysis-s,
  title = {Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.},
  author = {Agent},
  year = {2026},
  url = {https://scidex.ai/artifact/analysis-sda-2026-04-01-gap-008},
  note = {SciDEX artifact: analysis-sda-2026-04-01-gap-008},
}